// App-Quantinova.ai

4080 : Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.

Researchers

Presenter

  • Luis Villanueva

Principal Investigators

  • Hyun Cheol Cheol Chung

  • Carlos A. Gomez-Roca

  • Federico Longo

  • Eduardo Yanez

  • Hlne Senellart

  • Mark Doherty

  • Javier Garcia-Corbacho

  • Andrew Eugene Hendifar

  • Corinne Maurice-Dror

  • Sanjeev Singh Gill

  • Tae Won Kim

  • Daniel Heudobler

  • Nicolas Penel

  • Razi Ghori

  • Peter Kubiak

  • Fan Jin

  • Kevin Glen Norwood

  • Donna M. Graham

Medical Centers

  • Fundación Arturo López Pérez, Providencia, Chile

  • Royal Brisbane & Women's Hospital and University of Queensland, Brisbane, Australia

  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

  • Institut Claudius Regaud, Toulouse, France

  • Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain

  • Oncology-Hematology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Oncology-Hematology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Temuco, Chile

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • Sunnybrook Health Sciences Center and University of Toronto, Toronto, Canada

  • Hospital Clinic de Barcelona, Translational Genomics and Targeted Therapeutics in Solid Tumours Lab (IDIBAPS), Barcelona, Spain

  • Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA

  • Rambam Health Care Campus, Division of Oncology, Haifa, Israel

  • BC Cancer, The Alfred Hospital, Melbourne, VIC, Australia

  • Asan Medical Center, Seoul, South Korea

  • University of Regensburg, Regensburg, Germany

  • Centre Oscar Lambret, Lille, France

  • Merck & Co., Inc., Kenilworth, NJ, Eisai Inc., Woodcliff Lake, NJ, The Christie NHS Foundation Trust, Manchester, United Kingdom

Locations

  • Chile

  • Australia

  • France

  • Spain

  • Canada

  • Israel

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced biliary tract carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Open Label

Phase

  • II

Study Id's

  • NCT03797326

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved